Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 79

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 79
---
,682 (4,022)14,704 (366)%Facilities-related (including depreciation)18,677 16,711 1,966 12 %Other indirect R&D costs9,489 45,547 (36,058)(79)%Contra R&D expenses(673,433)(344,920)(328,513)95 %Total indirect R&D costs533,500 1,142,496 (608,996)(53)%Total R&D expenses$1,175,168 $2,681,772 $(1,506,604)(56)%1.The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (3) below. 2.For the three months ended September 30, 2025, amount also includes expenses for DARE to PLAY Sildenafil Cream.3.These contra R&D expenses were recognized as follows for the three months ended September 30, 2025 and 2024: (a) Ovaprene, $1.0 million, and $0, respectively; (b) other advanced clinical stage programs, $0.7 million and $0 respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $0.1 million and $0.1 million, respectively; and (d) preclinical stage programs, $2.6 million and $1.0 million, respectively.

The decrease of approximately $1.5 million in R&D expenses for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024 was primarily attributable to (i) an increase in contra R&D expenses in both direct program costs and indirect costs, (ii) a decrease in manufacturing costs related to Ovaprene, and (iii) a decrease in personnel costs, partially offset by increases in costs related to development activities for (A) our preclinical stage programs - primarily attributable to our DARE-LARC1 program, (B) our other advanced clinical stage programs - primarily attributable to our DARE-HPV program, (C) Sildenafil Cream and DARE to PLAY Sildenafil Cream, and (D) our Phase 1 and Phase 1-ready clinical stage programs - primarily attributable to our DARE-